Stock Performance and Market Context
On 31 Dec 2025, Poly Medicure Ltd recorded its lowest price in the last 52 weeks at Rs.1684.6, continuing a seven-day losing streak that has resulted in a cumulative decline of 6.72%. The stock’s daily performance lagged behind its sector by 0.36%, trading within a narrow range of Rs.14.45. Notably, the share price is currently below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex opened 118.50 points higher and was trading at 84,940.88, up 0.31%, approaching its 52-week high of 86,159.02 by 1.43%. The Sensex’s bullish trend is supported by its 50-day moving average trading above the 200-day moving average. Additionally, the BSE Small Cap index led gains with an increase of 0.85%, highlighting a divergence between Poly Medicure’s performance and broader market trends.
Financial Metrics and Valuation Analysis
Poly Medicure’s one-year performance starkly contrasts with the Sensex’s 8.72% gain, as the stock has declined by 35.06%. Despite this, the company’s profits have increased by 22.8% over the same period, indicating growth in earnings that has not translated into share price appreciation. The Price/Earnings to Growth (PEG) ratio stands at 2.1, suggesting that the stock’s price growth has not kept pace with earnings growth.
The company’s Return on Equity (ROE) is 12.4%, but it carries a high Price to Book Value ratio of 5.9, reflecting a valuation considered very expensive relative to its book value. This valuation is in line with the company’s peers’ average historical valuations, indicating that the market may be pricing in expectations that are not currently being met.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Dividend and Receivables Efficiency
The company’s dividend payout ratio (DPR) is notably low at 10.70%, which may be a factor in investor sentiment. Additionally, the debtors turnover ratio for the half-year period is 4.02 times, the lowest among its peers, indicating slower collection of receivables. These metrics suggest areas where the company’s financial efficiency is under pressure.
Debt and Institutional Holdings
Poly Medicure maintains a low average debt-to-equity ratio of zero, reflecting a debt-free capital structure. This conservative financial stance reduces leverage risk but has not prevented the stock’s decline. Institutional investors hold 23.31% of the company’s shares, a relatively high proportion that indicates significant participation by entities with advanced analytical capabilities.
Sector Position and Market Capitalisation
With a market capitalisation of Rs.17,181 crore, Poly Medicure is the second largest company in the Healthcare Services sector, representing 15.08% of the sector’s total market cap, second only to Lenskart Solutions. Its annual sales of Rs.1,712.13 crore account for 15.86% of the industry’s revenue, underscoring its substantial presence within the sector.
Holding Poly Medicure Ltd from Healthcare Services? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Ratings and Market Sentiment
Poly Medicure’s Mojo Score currently stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold as of 28 May 2025. The market cap grade is 3, reflecting its sizeable but not top-tier valuation within the market. The downgrade in rating aligns with the stock’s recent price weakness and underperformance relative to the sector and broader indices.
Comparative Market Performance
Over the past year, while the BSE500 index has generated returns of 6.13%, Poly Medicure has delivered negative returns of -35.06%, highlighting a significant divergence from market trends. This underperformance is notable given the company’s profit growth and sector standing, suggesting that valuation and market sentiment factors have weighed heavily on the stock price.
Conclusion
The fall of Poly Medicure Ltd to its 52-week low of Rs.1684.6 reflects a complex interplay of valuation concerns, dividend policy, receivables efficiency, and market sentiment. Despite profit growth and a strong sector position, the stock has lagged behind both its sector and the broader market indices. The downgrade to a Sell rating and the stock’s trading below all major moving averages underscore the challenges faced by the company in regaining investor confidence.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
